{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:38:54Z","timestamp":1793659134856,"version":"4.5.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Enzyvant Therapeutics"},{"name":"Sumitomo Pharma America, Inc"},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1K23HL171867-01"],"award-info":[{"award-number":["1K23HL171867-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Wearable devices provide an objective measurement of activity in the home setting and are complementary to 6-minute walk distance. Patients with pulmonary arterial hypertension (PAH) have low daily activity time, which is likely related to physiologic impairment and behavioral changes. Actigraphy may be a functional outcome assessment capable of detecting changes in activity mediated by improvement in physiology in a therapy trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>ELEVATE-2 was a phase 2 trial evaluating rodatristat ethyl versus placebo in PAH. We hypothesized rodatristat ethyl would improve measures of activity, specifically peak steps, at week 24, and further that changes in actigraphy measures would correlate with changes in stroke volume index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ELEVATE-2 was a randomized, double-blinded, placebo-controlled trial. All participants wore an ActiGraph on their wrist. We compared changes in average peak 5-minute steps (steps during the most active 5\u2009minutes of a day, whether or not consecutive), daily steps, moderate activity time, and vigorous activity time at baseline, week 12, and week 24. Linear mixed methods with repeated measures were performed to assess treatment\u2013time interaction at week 24, and least squares means were used to compare groups. Linear regression was performed to evaluate the changes in stroke volume index on activity parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 108 participants, 100 were included in the analysis. Adjusted least squares mean showed that peak 5-minute steps (-49 steps [95% CI, -80 to -18]), moderate activity time (-17.3\u2009minutes\/day [95% CI, -29.3 to -5.3]), and daily steps (-656 [95% CI, -1171 to -140]) all decreased at week 24 after treatment with rodatristat ethyl compared to placebo. Peak 5-minute steps were weakly associated with changes in stroke volume index (0.74 [95% CI, 0.11-1.37]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rodatristat ethyl reduced multiple activity parameters in this small, randomized multicenter study. Peak steps, daily steps, and moderate activity time seem to capture different aspects of movement in the home setting. Activity parameters were not strongly associated with resting hemodynamics, underscoring the influence of behavioral and external factors on activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trials registration<\/jats:title>\n                    <jats:p>NCT04712669.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/annalsats\/aaoaf066","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:02:32Z","timestamp":1769158952000},"page":"754-761","source":"Crossref","is-referenced-by-count":3,"title":["Rodatristat ethyl decreases activity in pulmonary arterial hypertension: results from the ELEVATE-2 trial"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3441-8264","authenticated-orcid":false,"given":"Daniel J","family":"Lachant","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0672-1680","authenticated-orcid":false,"given":"Sandeep","family":"Sahay","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Houston Methodist Hospital , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-7585","authenticated-orcid":false,"given":"Robert","family":"Block","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Rochester Medical Center , Rochester, NY,","place":["United States"]},{"name":"Division of Cardiology, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2918-597X","authenticated-orcid":false,"given":"Deborah","family":"Ossip","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Denning","sequence":"additional","affiliation":[{"name":"Sumitomo Pharma America, Inc (formerly Enzyvant) , Morrisville, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8231-3710","authenticated-orcid":false,"given":"Howard M","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Sumitomo Pharma America, Inc (formerly Enzyvant) , Morrisville, NC,","place":["United States"]},{"name":"Avalyn Pharma , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Parsley","sequence":"additional","affiliation":[{"name":"Sumitomo Pharma America, Inc (formerly Enzyvant) , Morrisville, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1399-5206","authenticated-orcid":false,"given":"R James","family":"White","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2026050720453087200_aaoaf066-B1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2026050720453087200_aaoaf066-B2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026050720453087200_aaoaf066-B3","doi-asserted-by":"publisher","first-page":"e12355","DOI":"10.1002\/pul2.12355","article-title":"Cardiac effort and 6-min walk distance correlate with stroke volume measured by cardiac magnetic resonance imaging","volume":"14","author":"Lachant","year":"2024","journal-title":"Pulm Circ"},{"key":"2026050720453087200_aaoaf066-B4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","article-title":"Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension","volume":"161","author":"Miyamoto","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2026050720453087200_aaoaf066-B5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1164\/rccm.202405-0914SO","article-title":"Contemporary treatment of pulmonary arterial hypertension: a U.S. perspective","volume":"210","author":"Sahay","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026050720453087200_aaoaf066-B6","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050720453087200_aaoaf066-B7","doi-asserted-by":"publisher","first-page":"105933","DOI":"10.1016\/j.rmed.2020.105933","article-title":"Six-minute walk distance in healthy young adults","volume":"165","author":"Halliday","year":"2020","journal-title":"Respir Med"},{"key":"2026050720453087200_aaoaf066-B8","doi-asserted-by":"publisher","first-page":"2045894020972572","DOI":"10.1177\/2045894020972572","article-title":"Heart rate monitoring improves clinical assessment during 6-min walk","volume":"10","author":"Lachant","year":"2020","journal-title":"Pulm Circ"},{"key":"2026050720453087200_aaoaf066-B9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.vph.2005.03.003","article-title":"The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect","volume":"43","author":"Frost","year":"2005","journal-title":"Vascul Pharmacol"},{"key":"2026050720453087200_aaoaf066-B10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.21693\/1933-088X-22.2.92","article-title":"Wearable devices in pulmonary arterial hypertension: what are we trying to learn?","volume":"22","author":"Lachant","year":"2023","journal-title":"Adv Pulm Hypertens"},{"key":"2026050720453087200_aaoaf066-B11","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1164\/rccm.202410-1929OC","article-title":"Positioning imatinib for pulmonary arterial hypertension: a dose finding phase 2 study","volume":"211","author":"Rothman","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026050720453087200_aaoaf066-B12","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.202104-1035LE","article-title":"Daily step counts are associated with hospitalization risk in pulmonary arterial hypertension","volume":"204","author":"Marvin-Peek","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026050720453087200_aaoaf066-B13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00408-019-00239-y","article-title":"Counting steps: a new way to monitor patients with pulmonary arterial hypertension","volume":"197","author":"Sehgal","year":"2019","journal-title":"Lung"},{"key":"2026050720453087200_aaoaf066-B14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.chest.2022.08.2231","article-title":"Assessing daily life physical activity by actigraphy in pulmonary arterial hypertension: insights from the randomized controlled study with selexipag (TRACE)","volume":"163","author":"Howard","year":"2023","journal-title":"Chest"},{"key":"2026050720453087200_aaoaf066-B15","doi-asserted-by":"publisher","first-page":"e12285","DOI":"10.1002\/pul2.12285","article-title":"Peak steps: capacity for activity improves after adding approved therapy in pulmonary arterial hypertension","volume":"13","author":"Lachant","year":"2023","journal-title":"Pulm Circ"},{"key":"2026050720453087200_aaoaf066-B16","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1164\/rccm.202402-0371OC","article-title":"Pulmonary hypertension and anastrozole (PHANTOM): a randomized, double-blind, placebo-controlled trial","volume":"210","author":"Kawut","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026050720453087200_aaoaf066-B17","first-page":"100219","article-title":"Peak steps to measure \u201ccapacity for activity\u201d: actigraphy in the ADAPT registry with oral treprostinil","volume-title":"JHLT Open","author":"Lachant","year":"2025"},{"key":"2026050720453087200_aaoaf066-B18","doi-asserted-by":"publisher","first-page":"2400175","DOI":"10.1183\/13993003.00175-2024","article-title":"Electronically delivered rehabilitation after acute pulmonary embolism is safe and improves quality of life","volume":"64","author":"Lachant","year":"2024","journal-title":"Eur Respir J"},{"key":"2026050720453087200_aaoaf066-B19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2213-2600(24)00226-1","article-title":"Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial","volume":"12","author":"Sitbon","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026050720453087200_aaoaf066-B20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.chest.2020.02.016","article-title":"A randomized, double-blind, placebo-controlled study of pulsed, inhaled nitric oxide in subjects at risk of pulmonary hypertension associated with pulmonary fibrosis","volume":"158","author":"Nathan","year":"2020","journal-title":"Chest"},{"key":"2026050720453087200_aaoaf066-B21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.chest.2016.02.633","article-title":"Physical activity and symptoms in pulmonary arterial hypertension","volume":"150","author":"Matura","year":"2016","journal-title":"Chest"},{"key":"2026050720453087200_aaoaf066-B22","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.chest.2021.04.012","article-title":"A mobile health intervention to increase physical activity in pulmonary arterial hypertension","volume":"160","author":"Hemnes","year":"2021","journal-title":"Chest"},{"key":"2026050720453087200_aaoaf066-B23","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1378\/chest.12-0150","article-title":"Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension","volume":"142","author":"Pugh","year":"2012","journal-title":"Chest"},{"key":"2026050720453087200_aaoaf066-B24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/ehjdh\/ztab095","article-title":"Comparison of chest- and wrist-based actigraphy in pulmonary arterial hypertension","volume":"3","author":"Lachant","year":"2022","journal-title":"Eur Heart J Digit Health"},{"key":"2026050720453087200_aaoaf066-B25","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1164\/rccm.202407-1397RL","article-title":"Exercise limitation in pulmonary hypertension\u2014physiological insights into the 6-minute walk test","volume":"210","author":"Kremer","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026050720453087200_aaoaf066-B26","doi-asserted-by":"publisher","first-page":"e70097","DOI":"10.1002\/pul2.70097","article-title":"Characteristics of daily walking bouts as valid and reliable indicators of exercise capacity in pulmonary arterial hypertension: insights from the randomized controlled study with selexipag (TRACE)","volume":"15","author":"Rehman","year":"2025","journal-title":"Pulm Circ"},{"key":"2026050720453087200_aaoaf066-B27","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A6617","article-title":"Inhaled nitric oxide in fibrotic lung disease: a randomized, double-blind, placebo-controlled trial","volume":"21","author":"Nathan","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026050720453087200_aaoaf066-B28","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026050720453087200_aaoaf066-B29","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1513\/AnnalsATS.202107-864OC","article-title":"A phase-2 exploratory randomized controlled trial of INOpulse in patients with fibrotic interstitial lung disease requiring oxygen","volume":"19","author":"King","year":"2022","journal-title":"Ann Am Thorac Soc"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/advance-article-pdf\/doi\/10.1093\/annalsats\/aaoaf066\/66511402\/aaoaf066.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/5\/754\/66511402\/aaoaf066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/5\/754\/66511402\/aaoaf066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:45:41Z","timestamp":1778201141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/23\/5\/754\/8435338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,23]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/annalsats\/aaoaf066","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,23]]}}}